Search Result

Results for "

Insulin Receptor Agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Insulin Receptor (7) Adenosine Receptor (1) Adenylate Cyclase (2) Adrenergic Receptor (1) Androgen Receptor (1) Angiotensin Receptor (1) Calcium Channel (1) CGRP Receptor (1) Free Fatty Acid Receptor (9) FXR (1) G protein-coupled Bile Acid Receptor 1 (1) G Protein-coupled Receptor Kinase (GRK) (1) GCGR (2) GLP Receptor (5) Glucocorticoid Receptor (3) Neuropeptide Y Receptor (2) Potassium Channel (1) PPAR (2) RXFP Receptor (1) Somatostatin Receptor (4)
By Research Areas:	Cancer (1) Cardiovascular Disease (6) Endocrinology (5) Inflammation/Immunology (7) Metabolic Disease (32) Neurological Disease (1)

By Targets:

Insulin Receptor (7)

Adenosine Receptor (1)

Adenylate Cyclase (2)

Adrenergic Receptor (1)

Androgen Receptor (1)

Angiotensin Receptor (1)

Calcium Channel (1)

CGRP Receptor (1)

Free Fatty Acid Receptor (9)

FXR (1)

G protein-coupled Bile Acid Receptor 1 (1)

G Protein-coupled Receptor Kinase (GRK) (1)

GCGR (2)

GLP Receptor (5)

Glucocorticoid Receptor (3)

Neuropeptide Y Receptor (2)

Potassium Channel (1)

PPAR (2)

RXFP Receptor (1)

Somatostatin Receptor (4)

By Research Areas:

Cancer (1)

Cardiovascular Disease (6)

Endocrinology (5)

Inflammation/Immunology (7)

Metabolic Disease (32)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Insulin Receptor IGF-1R

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3584A

(Pro3) GIP, human TFA (Pro3) Gastric Inhibitory Peptide, human TFA	Insulin Receptor	Metabolic Disease
(Pro3) GIP, human TFA is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human TFA has high binding affinity for human GIPR with K_i/ K_d value of 0.90 nM. (Pro3) GIP, human TFA human can be used for the research of obesity-related diabetes .

HY-P99665

Insulin efsitora alfa LY-3209590	Insulin Receptor	Metabolic Disease
Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .

HY-14234

Glucocorticoid receptor agonist 1 Publications Verification	Glucocorticoid Receptor	Metabolic Disease Inflammation/Immunology Endocrinology
Glucocorticoid receptor agonist is a Glucocorticoid receptor agonist that acts on Glucocorticoid receptor (GR), progesterone receptor (PR) and mineralocorticoid receptor (MR) with the IC₅₀ values of 2.1 , 1200 and 210 nM, respectively. Glucocorticoid receptor agonist has steroid-like anti-inflammatory properties and may be used to improve metabolism and reduce increased levels of body fat and serum insulin .

HY-112606

ML-290	RXFP Receptor	Others
ML-290 is a first-in-class and potent relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC₅₀ of 94 nM . ML290 is a biased allosteric agonist at the relaxin receptor RXFP1.

HY-169066

INSR agonist 1	Insulin Receptor	Metabolic Disease
INSR agonist 1 is an insulin receptor (INSR) agonist. INSR agonist 1 can increase INSR pY1355/1361 levels and works synergistically with insulin .

HY-139709

Glucocorticoids receptor agonist 1	Glucocorticoid Receptor	Inflammation/Immunology
Glucocorticoids receptor agonist 1 is a potent anti-inflammatory, arylpyrazole-based glucocorticoid receptor agonist that does not impair insulin secretion.

HY-139710

Glucocorticoids receptor agonist 2	Glucocorticoid Receptor	Inflammation/Immunology
Glucocorticoids receptor agonist 2 is a potent anti-inflammatory, arylpyrazole-based glucocorticoid receptor agonist that does not impair insulin secretion.

HY-118141

BMS-194449	Adrenergic Receptor	Metabolic Disease
BMS-194449 is a beta 3 receptor agonist with the K_i value of 160 nM. BMS-194449 can be used for study of obesity and non-insulin dependent diabetes .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P3255

DA-JC4	Insulin Receptor	Neurological Disease Inflammation/Immunology
DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways .

HY-101637

Reglitazar JT 501	PPAR	Metabolic Disease
Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels .

HY-162136

GPR40 agonist 7	Free Fatty Acid Receptor	Metabolic Disease
GPR40 agonist 7 (Compound 1) is an orally active G protein-coupled receptor 40 (GPR40) agonist. GPR40 agonist 7 can significantly increase insulin and GLP-1 secretion, and has a hypoglycemic effect in vivo with an ED₅₀ of 0.58 mg/kg

HY-109692

GPR120 Agonist 5	Free Fatty Acid Receptor	Metabolic Disease Inflammation/Immunology
GPR120 Agonist 5 (compound 12) is an agonist targeting GPR120 (EC₅₀=1.2 μM). GPR120 Agonist 5 promotes the release of glucagon-like 1 (GLP-1) by binding to the GPR120 receptor, which in turn binds to its receptors on pancreatic beta cells, increasing insulin secretion and thereby lowering blood sugar levels. GPR120 Agonist 5 also helps reduce chronic low-grade inflammation, which plays an important role in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. GPR120 Agonist 5 can be used to investigate the mechanism of action of GPR120 in metabolic and inflammatory diseases .

HY-P10302A

GLP-1R/GIPR agonist-1 (soduim)	GLP Receptor	Metabolic Disease
GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC₅₀ is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC₅₀ is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-151959

FXR agonist 4	FXR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC₅₀ value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .

HY-P4685

(Sar1,Ile4,8)-Angiotensin II	Angiotensin Receptor	Metabolic Disease
(Sar1,Ile4,8)-Angiotensin II is a functionally selective *angiotensin II type 1 receptor* (AT1R)** agonist. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β .

HY-164040

Zavolosotine	Somatostatin Receptor	Metabolic Disease
Zavolosotine (Compound 1) is an orally active agonist for somatostatin receptor type 5 (SST5) with EC₅₀ <1 nM. Zavolosotine inhibits insulin and glucagon secretion, increases levels of glucagon in blood in rat model .

HY-108664

MRS2957	Others	Metabolic Disease
MRS2957 is a P2Y6 receptor agonist that activates AMPK in pancreatic β-cells, promoting insulin secretion and reducing apoptosis, thereby holding potential as a therapeutic target for type 2 diabetes.

HY-14229

TGR5 Receptor Agonist 2 Publications Verification CCDC	G protein-coupled Bile Acid Receptor 1 Calcium Channel	Metabolic Disease
TGR5 Receptor Agonist (CCDC), a potent *Takeda G protein-coupled receptor* 5 (TGR5; GPCR19)** agonist, shows improved potency in the U2-OS cells and melanophore cells with pEC₅₀s of 6.8 and 7.5, respectively. TGR5 Receptor Agonist can induce peripheral and central hypersensitivity to bladder distension in mice, and increase intracellular Ca ²⁺ concentration. TGR5 Receptor Agonist can also reduces food intake and improves insulin responsiveness, in diet-induced obese mice. TGR5 Receptor Agonist can be used to research diabetes, bladder hypersensitivity and anti-obesity .

HY-106181A

Rivoglitazone hydrochloride R-106056 hydrochloride	PPAR	Metabolic Disease
Rivoglitazone hydrochloride (R-106056 hydrochloride) is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist. Rivoglitazone hydrochloride (R-106056 hydrochloride) exerts its anti-diabetic effect by activating PPARγ to regulate the expression of a large number of genes related to lipid and glucose metabolism. Rivoglitazone hydrochloride (R-106056 hydrochloride) can be used to study insulin secretion and insulin resistance in animal models of diabetes .

HY-P2541

GIP (1-30) amide, porcine	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P2541A

GIP (1-30) amide, porcine TFA 1 Publications Verification	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-P1072

PHM-27 (human)	CGRP Receptor	Cardiovascular Disease Metabolic Disease
PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the human calcitonin receptor agonist with an EC₅₀ of 11 nM. PHM-27 (human) efficiently enhances glucose-induced insulin secretion from beta cells by an autocrine mechanism .

HY-120287

L-054522	Somatostatin Receptor	Endocrinology
L-054522 is an agonist for *somatostatin receptor* subtype 2 with K_d of 0.01 nM. L-054522 inhibits growth hormone release from rat primary pituitary cell (IC₅₀*=0.05 nM) and glucagon and insulin* release from isolated mouse pancreatic islet cell (IC₅₀=0.05 nM and 12 nM) .

HY-P10413

SHBG(141–161)	Androgen Receptor	Metabolic Disease Endocrinology
SHBG 141-161 is a GPRC6A receptor agonist. SHBG 141-161 mimics the action of GPRC6A endogenous agonist uncarboxylated osteocalcin by binding to GPRC6A and promoting downstream signaling to increase testosterone and insulin secretion. SHBG 141-161 also reduces the affinity of GPRC6A to GDP protein by binding to the outer cell domain of GPRC6A thus affecting the dynamics of signal transduction. SHBG 141-161 can be used to study GPRC6A in energy metabolism and endocrine regulation .

HY-129707

AMG 837 hemicalcium	Free Fatty Acid Receptor	Metabolic Disease
AMG 837 hemicalcium is a potent, orally bioavailable and partial agonist of GPR40/FFA1. AMG 837 hemicalcium inhibits specific [ ³H]AMG 837 binding at the human FFA1 receptor with a pIC₅₀ of 8.13. AMG 837 hemicalcium could enhance insulin secretion and lower glucose levels in rodents .

HY-19310

AMP-579	Adenosine Receptor	Cardiovascular Disease Metabolic Disease
AMP-579 is an adenosine receptor agonist that primarily targets adenosine A1 and A2_A receptors (with K_i values of 1.7 and 4.5 nM for the A1 receptor in rat brain and adipocytes, and a K_i value of 56 nM for the A2_A receptor in rat brain). AMP-579 inhibits lipolysis, restores insulin-dependent glucose transport, and reduces heart rate through the activation of A1 receptors, while it induces vasodilation, particularly in coronary arteries, through the activation of A2_A receptors (with an IC₅₀ of 0.3 μM in porcine coronary arterial rings). AMP 579 shows potential for application in cardioprotection and the treatment of acute myocardial infarction .

HY-19835

LY2922470	Free Fatty Acid Receptor	Metabolic Disease
LY2922470 is a potent, selective and orally available agonist of the *G protein-coupled receptor* 40 (GPR40), with EC₅₀*s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with significant increases in insulin* and GLP-1, is potential for the treatment of type 2 diabetes mellitus (T2DM) .

HY-P2090

Angiopeptin	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .

HY-12976

DS-1558	G Protein-coupled Receptor Kinase (GRK)	Metabolic Disease
DS-1558 is an orally active small molecule *G protein-coupled receptor* 40** agonist. DS-1558 not only increases the glucose-stimulated insulin secretion by glucagon like peptide-1 (GLP-1) but also potentiated the maximum insulinogenic effects of GLP-1 after an intravenous glucose injection in normal Sprague Dawley rats. DS-1558 is promising for research of type 2 diabetes .

HY-P2090A

Angiopeptin TFA	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .

HY-108020

LY2881835	Free Fatty Acid Receptor	Endocrinology
LY2881835 is a potent and selective agonist of G protein-coupled receptor 40 (GPR40). LY2881835 has efficacious and durable dose-dependent reductions in glucose levels along with significant increases in insulin and GLP-1 secretion. LY2881835 has the potential for the research of type 2 diabetes mellitus . LY2881835 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-15589

GW9508 5 Publications Verification	Free Fatty Acid Receptor Potassium Channel	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GW9508 is a potent and selective *G protein-coupled receptors* FFA1 (GPR40) and GPR120** agonist with pEC₅₀s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (K_ATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .

HY-14363

TUG-424	Free Fatty Acid Receptor	Metabolic Disease
TUG-424 is a potent and selective *free fatty acid receptor* 1 (FFA1/GPR40)** agonist with an EC₅₀ of 32 nM. TUG-424 significantly increases glucose-stimulated insulin secretion at 100 nM. TUG-424 may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity . TUG-424 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P1128

Galanin (swine)	Neuropeptide Y Receptor	Metabolic Disease
Galanin (swine), a neuropeptide, consists of 29 amino acids and contains a C-terminal amidated glycine. Galanin (swine) inhibits basal and stimulated insulin secretion both in vivo and in vitro under a variety of experimental conditions. Galanin (swine) is a galanin receptor agonist with pK_is of 9.63, 9.49, 9.02, 8.98, 8.01 and 8.14 at human GAL1, rat GAL1, human GAL2, rat GAL2, human GAL3 and rat GAL3 respectively .

HY-P1128A

Galanin (swine) (TFA)	Neuropeptide Y Receptor	Metabolic Disease
Galanin (swine) TFA, a neuropeptide, consists of 29 amino acids and contains a C-terminal amidated glycine. Galanin (swine) inhibits basal and stimulated insulin secretion both in vivo and in vitro under a variety of experimental conditions. Galanin (swine) TFA is a galanin receptor agonist with pK_is of 9.63, 9.49, 9.02, 8.98, 8.01 and 8.14 at human GAL1, rat GAL1, human GAL2, rat GAL2, human GAL3 and rat GAL3 respectively .

HY-13967B

AMG 837 calcium hydrate 1 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
AMG 837 calcium hydrate is a potent, orally bioavailable and partial agonist of GPR40/FFA1. AMG 837 calcium hydrate inhibits specific [ ³H]AMG 837 binding at the human FFA1 receptor with a pIC₅₀ of 8.13. AMG 837 calcium hydrate could enhance insulin secretion and lower glucose levels in rodents . AMG 837 (calcium hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-19995

GSK137647A 1 Publications Verification GSK 137647	Free Fatty Acid Receptor	Metabolic Disease
GSK137647A (GSK 137647) is a potent, selective *free fatty acid receptor* 4 (FFA4*) agonist* with pEC₅₀ values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC₅₀ values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively. GSK137647A has anti-inflammatory activity. GSK137647A induces insulin secretion and inhibits epithelial ion transport, GSK137647A is related to regulation of glucose homeostasis and anti-inflammatory response .

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .

HY-113513

5-HEPE	Others	Cancer
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

Cat. No.	Product Name	Target	Research Area